Chlorphenamine

Chlorphenamine

Clinical data
Pregnancy category	AU: A US: B (No risk in non-human studies)
Routes of administration	Oral, IV, IM, SC
ATC code	R06AB04 (WHO)
Legal status
Legal status	AU: S3 (Pharmacist only) UK: General sales list (GSL, OTC) US: OTC (for oral forms)
Pharmacokinetic data
Bioavailability	25 to 50%
Protein binding	72%
Metabolism	Hepatic (CYP2D6)
Elimination half-life	21-27 hours
Excretion	Renal
Identifiers
IUPAC name 3-(4-chlorophenyl)-N,N-dimethyl- 3-pyridin-2-yl-propan-1-amine
CAS Number	132-22-9
PubChem CID	2725
DrugBank	APRD00001
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C16H19ClN2
Molar mass	274.788 g/mol
Solubility in water	0.55 g/100 mL, liquid mg/mL (20 °C)

Chlorphenamine (INN) or chlorpheniramine (USAN, former BAN), commonly marketed as its salt chlorphenamine maleate (CPM; Chlor-Trimeton®, Piriton®, Chlor-Tripolon®), is a first-generation antihistamine used in the prevention of the symptoms of allergic conditions such as rhinitis and urticaria. Its sedative effects are relatively weak compared to other first-generation antihistamines.

Chlorphenamine has antidepressant properties, inhibiting reuptake of the neurotransmitter serotonin. Based on this knowledge, the Swedish company Astra AB was able to derive the first marketed selective serotonin reuptake inhibitor, zimelidine, from chlorphenamine.

See also

• Coricidin
• Chlorpheniramine and phenylpropanolamine
• Dexchlorpheniramine

File:DSC000776.JPG

Chlorphenamine 4mg from U.K.

References

• Bruce G. Charlton, Self-management of psychiatric symptoms using over-the-counter (OTC) psychopharmacology: the S-DTM therapeutic model - self-diagnosis, self-treatment, self-monitoring. Medical Hypotheses 2005; 65: 823-828.